Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TP-1454 |
Synonyms | |
Therapy Description |
TP-1454 is a pyruvate kinase M2 (PKM2) activator, which may inhibit tumor cell viability and tumor growth, and enhance anti-tumor immune response in combination with other agents (Mol Cancer Ther December 1 2019 (18) (12 Supplement) B080). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TP-1454 | TP1454|TP 1454 | TP-1454 is a pyruvate kinase M2 (PKM2) activator, which may inhibit tumor cell viability and tumor growth, and enhance anti-tumor immune response in combination with other agents (Mol Cancer Ther December 1 2019 (18) (12 Supplement) B080). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04328740 | Phase I | Ipilimumab + Nivolumab + TP-1454 TP-1454 | Phase 1 Study of Oral TP-1454 | Active, not recruiting | USA | 0 |